MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Suletud

SektorTervishoid

24.09 2.73

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.92

Max

24.23

Põhinäitajad
By Trading Economics
Sissetulek	-14M -50M
Müük	12M 128M
Kasumimarginaal	-39.506
Töötajad	1,784
EBITDA	-17M -48M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+42.41% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	200M 2.4B
Eelmine avamishind	21.36
Eelmine sulgemishind	24.09

Uudiste sentiment

By Acuity

43%

57%

115 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

28.13 / 31.12 Toetus ja vastupanu

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. apr 2026, 23:48 UTC

Uudisväärsed sündmused

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19. apr 2026, 23:36 UTC

Uudisväärsed sündmused

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19. apr 2026, 22:47 UTC

Uudisväärsed sündmused

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19. apr 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19. apr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19. apr 2026, 23:38 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19. apr 2026, 23:12 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19. apr 2026, 23:10 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19. apr 2026, 23:09 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19. apr 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18. apr 2026, 01:00 UTC

Uudisväärsed sündmused

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

42.41% tõus

12 kuu keskmine prognoos

Keskmine 34.45 USD 42.41%

Kõrge 47 USD

Madal 21.8 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.13 / 31.12Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

115 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.